Skip to content Skip to footer
Insight+_Ridhi Rastogi

New Drug Designations – March 2025 

Shots:      PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, and NMPA    The March 2025 report covers designations granted to 37 drugs and 3 medical devices, spanning 11 small molecules, 10 biologics, 10 cell and gene therapies & 3 medical devices among…

Read more

Spotlight_Jayasree Iyer

Reuters Pharma 2025: Post Conference Talks Featuring Jayasree K. Iyer 

Jayasree K. Iyer, CEO of Access to Medicine Foundation, moderated a panel discussion that featured leaders from the 2024 Access to Medicine Index. Jayasree highlighted how biopharma companies foster accessibility to essential medicines in low- and middle-income countries through global partnerships, innovation, and sustainable models. Jayasree talks about the future of Health Equity amidst the…

Read more

Viewpoints_Jesse Mendelsohn

Predicting 2025 Trends: Jesse Mendelsohn from Model N in an Illuminating Discussion with PharmaShots

Shots:  Several undulating factors coalesce to inadvertently shape the biopharma industry  Prominent challenges include mounting pressure on Pharmacy Benefit Managers from independent pharmacies and drug manufacturers, a growing shortage of GLP-1 drugs, and the addition of 15 more drugs to the Inflation Reduction Act’s price negotiation list.  Jesse Mendelsohn, SVP at Model N, emphasizes the…

Read more

Thoughtspot_Saurabh_Chaubey

Personalized Medicine: A Paradigm Shift in Modern Treatment Approach

Shots:   Precision medicine holds a promising foothold in addressing unmet healthcare needs and bridging the gaps in care accessibility and high treatment costs  Defying the one-size-fits-all model, personalized medicine offers therapies tailored to an individual’s physiology, lifestyle, and environment  With this article, let’s capture the intricacies of precision medicine by navigating the benefits, challenges, progress,…

Read more

Insights+: The US FDA New Drug Approvals in August 2023

The US FDA New Drug Approvals in March 2025

Shots:      PharmaShots has compiled a list of US FDA-approved drugs in the month of March 2025       The US FDA has approved a total of 2 new drug including 2 new molecular entities leading to the treatment of patients and advances in the healthcare industry        The major highlighted drug was GSK’s Blujepa securing approval for treating…

Read more

CXO Talks: Ali Jannati from Linus Health in a Stimulating Dialogue Exchange with PharmaShots

In the CXO Talks podcast, PharmaShots spoke with Ali Jannati, Director of Cognitive Science at Linus Health. Ali eloquently highlighted Linus’ journey to becoming a leader in digital brain health through its innovative digital cognitive assessment platform He emphasized the importance of digital biomarkers in evaluating brain function by capturing subtle nuances and response latencies,…

Read more

PharmaShots Announces Strategic Data Partnership with AlphaSense 

PharmaShots is pleased to announce a new strategic data partnership with AlphaSense, marking an important milestone in our mission to elevate the quality, accessibility, and impact of insights across the biopharma and healthcare ecosystem.  This collaboration strengthens our commitment to reimagining intelligence and delivering unmatched industry updates that empower researchers, students, analysts, and biopharma professionals worldwide. By…

Read more

PharmaShots Magazine-April-2025 Edition

PharmaShots Magazine-April-2025 Edition

Emerging technologies holds a promising foothold in redefining the aspects of preventative, diagnostic, therapeutic, and patient care in the healthcare landscape. 3D Bioprinting offers innovative approach to addressing unmet healthcare needs with efficacious precision medicine in life-threatening conditions and developing therapies and medical devices that mimic complex human physiology.  In April, PharmaShots Magazine is exploring…

Read more